Literature DB >> 29296871

Quality of life of Hurler syndrome patients after successful hematopoietic stem cell transplantation.

Mieke Aldenhoven1, Brigitte T A van den Broek1,2,3, Robert F Wynn4, Anne O'Meara5, Paul Veys6, Attilio Rovelli7, Simon A Jones8, Rossella Parini9, Peter M van Hasselt1,2,3, Marleen Renard10, Victoria Bordon11, Tom J de Koning12, Jaap Jan Boelens1,2,3.   

Abstract

Hurler syndrome (HS) is a lysosomal storage disease characterized by multisystem morbidity and death in early childhood. Hematopoietic stem cell transplantation (HSCT) results in long-term survival, although with significant residual disease burden. How this residual disease affects the health-related quality of life is unknown. Therefore, we conducted a multicenter cohort study on functional and psychosocial health and compared the outcomes to normative data using the Child Health Questionnaire and Pediatric Outcomes Data Collection Instrument. Perception of care was evaluated by the Measure of Processes of Care questionnaire. Sixty-three HS patients receiving HSCT with at least 3 years of follow-up after HSCT were included. The influence of potential predictors was analyzed using linear regression analysis, and correlation analysis was performed using Spearman rank correlation. Functional health of transplanted HS patients was significantly diminished compared with normative data (median physical summary z score, -2.4 [range, -3.5 to -1.6]; median global functioning z score, -3.2 [range, -4.8 to -1.8]). Psychosocial health was comparable or only slightly reduced compared with healthy peers (median psychosocial summary z score, 0.15 [range, -0.7 to 0.8]). A higher obtained lysosomal enzyme level post-HSCT predicted for superior functional health. Overall, parents were satisfied with the care received. Functional health of transplanted HS patients appeared significantly more affected than psychosocial health. To improve functional health, the use of only noncarrier donors and striving to achieve full-donor chimerism, both resulting in higher enzyme levels, is advised. Assessing the health-related quality of life could play an important role in evaluating outcomes of HS patients receiving novel (cell) therapies, including autologous gene-transduced HSCT.

Entities:  

Year:  2017        PMID: 29296871      PMCID: PMC5737136          DOI: 10.1182/bloodadvances.2017011387

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  11 in total

1.  Comparison of three outcomes instruments in children.

Authors:  J Pencharz; N L Young; J L Owen; J G Wright
Journal:  J Pediatr Orthop       Date:  2001 Jul-Aug       Impact factor: 2.324

Review 2.  The clinical outcome of Hurler syndrome after stem cell transplantation.

Authors:  Mieke Aldenhoven; Jaap Jan Boelens; Tom J de Koning
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

3.  Cord blood is the optimal graft source for the treatment of pediatric patients with lysosomal storage diseases: clinical outcomes and future directions.

Authors:  Mieke Aldenhoven; Joanne Kurtzberg
Journal:  Cytotherapy       Date:  2015-03-31       Impact factor: 5.414

4.  Quality of paediatric rehabilitation from the parent perspective: validation of the short Measure of Processes of Care (MPOC-20) in the Netherlands.

Authors:  Renate C Siebes; Gerard H Maassen; Lex Wijnroks; Marjolijn Ketelaar; Petra E M van Schie; Jan Willem Gorter; Adri Vermeer
Journal:  Clin Rehabil       Date:  2007-01       Impact factor: 3.477

5.  Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study.

Authors:  Mieke Aldenhoven; Robert F Wynn; Paul J Orchard; Anne O'Meara; Paul Veys; Alain Fischer; Vassili Valayannopoulos; Benedicte Neven; Attilio Rovelli; Vinod K Prasad; Jakub Tolar; Heather Allewelt; Simon A Jones; Rossella Parini; Marleen Renard; Victoria Bordon; Nico M Wulffraat; Tom J de Koning; Elsa G Shapiro; Joanne Kurtzberg; Jaap Jan Boelens
Journal:  Blood       Date:  2015-01-26       Impact factor: 22.113

6.  The Pediatric Orthopaedic Society of North America pediatric orthopaedic functional health questionnaire: an analysis of normals.

Authors:  R J Haynes; E Sullivan
Journal:  J Pediatr Orthop       Date:  2001 Sep-Oct       Impact factor: 2.324

7.  Capturing quality of life in pediatric orthopaedics: two recent measures compared.

Authors:  M G Vitale; D E Levy; A J Moskowitz; A C Gelijns; M Spellmann; L Verdisco; D P Roye
Journal:  J Pediatr Orthop       Date:  2001 Sep-Oct       Impact factor: 2.324

8.  Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model.

Authors:  Ilaria Visigalli; Stefania Delai; Letterio S Politi; Carmela Di Domenico; Federica Cerri; Emanuela Mrak; Raffaele D'Isa; Daniela Ungaro; Merel Stok; Francesca Sanvito; Elisabetta Mariani; Lidia Staszewsky; Claudia Godi; Ilaria Russo; Francesca Cecere; Ubaldo Del Carro; Alessandro Rubinacci; Riccardo Brambilla; Angelo Quattrini; Paola Di Natale; Katherine Ponder; Luigi Naldini; Alessandra Biffi
Journal:  Blood       Date:  2010-09-16       Impact factor: 22.113

9.  The POSNA pediatric musculoskeletal functional health questionnaire: report on reliability, validity, and sensitivity to change. Pediatric Outcomes Instrument Development Group. Pediatric Orthopaedic Society of North America.

Authors:  L H Daltroy; M H Liang; A H Fossel; M J Goldberg
Journal:  J Pediatr Orthop       Date:  1998 Sep-Oct       Impact factor: 2.324

10.  The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK.

Authors:  David Moore; Martin J Connock; Ed Wraith; Christine Lavery
Journal:  Orphanet J Rare Dis       Date:  2008-09-16       Impact factor: 4.123

View more
  6 in total

1.  Burden of Morbidity after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A BMT Survivor Study Report.

Authors:  Aman Wadhwa; Yanjun Chen; Lindsey Hageman; Elizabeth Schlichting; Erin Funk; Jessica Hicks; Nora Balas; Arianna Siler; Jessica Wu; Liton Francisco; Anna Holmqvist; Ashish Gupta; Troy Lund; Paul J Orchard; Saro Armenian; Mukta Arora; Smita Bhatia
Journal:  Transplant Cell Ther       Date:  2021-12-05

Review 2.  Precision Medicine for Lysosomal Disorders.

Authors:  Filippo Pinto E Vairo; Diana Rojas Málaga; Francyne Kubaski; Carolina Fischinger Moura de Souza; Fabiano de Oliveira Poswar; Guilherme Baldo; Roberto Giugliani
Journal:  Biomolecules       Date:  2020-07-26

3.  Hearing loss in patients with mucopolysaccharidoses-1 and -6 after hematopoietic cell transplantation: A longitudinal analysis.

Authors:  Brigitte T A van den Broek; Adriana L Smit; Jaap Jan Boelens; Peter M van Hasselt
Journal:  J Inherit Metab Dis       Date:  2020-07-09       Impact factor: 4.982

4.  Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT).

Authors:  N Guffon; M Pettazzoni; N Pangaud; C Garin; G Lina-Granade; C Plault; C Mottolese; R Froissart; A Fouilhoux
Journal:  Orphanet J Rare Dis       Date:  2021-01-31       Impact factor: 4.123

5.  Fetal therapies and trials for lysosomal storage diseases: a survey of attitudes of parents and patients.

Authors:  Marisa E Schwab; Julia E H Brown; Billie Lianoglou; Chengshi Jin; Patricia C Conroy; Renata C Gallagher; Paul Harmatz; Tippi C MacKenzie
Journal:  Orphanet J Rare Dis       Date:  2022-01-29       Impact factor: 4.123

Review 6.  Mucopolysaccharidosis Type I.

Authors:  Francyne Kubaski; Fabiano de Oliveira Poswar; Kristiane Michelin-Tirelli; Ursula da Silveira Matte; Dafne D Horovitz; Anneliese Lopes Barth; Guilherme Baldo; Filippo Vairo; Roberto Giugliani
Journal:  Diagnostics (Basel)       Date:  2020-03-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.